Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track BHVN with free AI briefings, catalyst countdowns, and dilution alerts.

BHVN · Biohaven Ltd.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

On the Downside Radar: financing pressure. About 5.0 months of cash at its recent burn rate (Sep 30, 2026 balance sheet), a shelf registration filed May 4, 2026, and no offering in the last 90 days. Of biotech stocks in this setup with 6 months of cash or less, 51% sold new shares within three months and 73% were lower 60 trading days later (median -24%). How we know
$161.1M Cash on Hand
5mo Cash Runway
12.7% Short Interest
$23.73 Analyst Target (15)
Follow BHVN by email Get an email when BHVN reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about BHVN, unsubscribe in one click. Privacy

📣 What BHVN Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Pegargiminase Glioblastoma Phase 2/3 · NCT03970447 Recruiting
TSP-1 Activator VT1021 Glioblastoma Phase 2/3 · NCT03970447 Recruiting
Verdiperstat Multiple System Atrophy Phase 3 · NCT03952806 Completed
Dianhydrogalactitol (VAL-083) Glioblastoma Phase 2/3 · NCT03970447 Recruiting
Troriluzole (BHV-4157) Obsessive Compulsive Disorder Phase 3 · NCT04708834 Terminated
Tinostamustine Glioblastoma Phase 2/3 · NCT03970447 Recruiting
Talditercept Alfa Spinal Muscular Atrophy Phase 3 · NCT05337553 Active not recruiting
Paxalisib Glioblastoma Phase 2/3 · NCT03970447 Recruiting
BHV-8000 10mg Parkinson Disease Phase 2/3 · NCT06976268 Recruiting
Opakalim Focal Epilepsy Phase 2/3 · NCT06309966 Active not recruiting
ATM Kinase Inhibitor AZD1390 Glioblastoma Phase 2/3 · NCT03970447 Recruiting
BHV-1400 IgA Nephropathy Phase 3 · NCT07642050 Not yet recruiting
BHV-1300 Graves Disease Phase 3 · NCT07661056 Recruiting
BHV-0223 Social Anxiety Disorder Phase 2/3 · NCT03017508 Completed
BHV-2100 Migraine Phase 2 · NCT06603623 Completed
Anti-TROP-2 Antibody-drug Conjugate PBI-410 Solid Tumor Phase 1/2 · NCT06384807 Recruiting

Also used in these trials (approved or third-party drugs, not BHVN's own candidates): Temozolomide, Regorafenib, Lomustine, Cemiplimab, Ipilimumab, Nivolumab, Riluzole.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

BHVN holds $161.1M in cash and short-term investments (as of Sep 30, 2026) and burns about $96M/quarter from operations, an estimated runway of 5 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 79 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when BHVN files for a raise →

👥 Who Owns BHVN

Insiders 15% Institutions (386 holders) 85% Public and other holders 0%
HolderTypeShares% of sharesAs of
Blackrock Inc. Institution (13F) 12,951,180 8.57% 2026-09-30
SUVRETTA CAPITAL MANAGEMENT, LLC Institution (13G, 5%+) 10,286,937 6.81% 2025-12-31
Montanova Capital LLC Institution (13F) 10,286,937 6.81% 2026-09-30
Stifel Financial Corporation Institution (13F) 9,941,685 6.58% 2026-09-30
John W Childs
Director · +117,001 options
Insider 9,876,729 6.54% 2025-11-13
Woodline Partners LP Institution (13G, 5%+) 7,660,280 5.07% 2026-06-30
State Street Corporation Institution (13F) 6,874,721 4.55% 2026-09-30
John Yetimoglu
Director
Insider 6,250,000 4.14% 2026-08-06
Infinitum Asset Management, LLC Institution (13F) 6,250,000 4.14% 2026-09-30
Rubric Capital Management LP Institution (13F) 4,875,000 3.23% 2026-09-30
Bank of America Corporation Institution (13F) 4,077,524 2.70% 2026-09-30
AQR Capital Management, LLC Institution (13F) 4,053,232 2.68% 2026-09-30

Share count 151,058,781 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-09-15
filed 2026-09-17
Gentile Kimberly
Option award (A) 1,000 – –
2026-04-28
filed 2026-04-30
Antonijevic Irina
Option award (A) 68,693 – –
2026-04-28
filed 2026-04-30
Mehta Kishan
Option award (A) 68,693 – –
2026-04-28
filed 2026-04-30
Heffernan Michael Thomas
Option award (A) 68,693 – –
2026-04-28
filed 2026-04-30
Bailey Gregory
Option award (A) 68,693 – –

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

📅 Past FDA Decisions & Stock Reactions

DateDrugTypeRun-up 30dDecision 1dAfter 5d
2025-05-14 Rare Disease NDA +10.7% +0.8% -16.7%

Browse all historical PDUFA outcomes →

Get the full BHVN picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for BHVN and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.